阿司匹林在房颤抗凝治疗中的弱化

doi:10.3969/j.issn.1000-8535.2015.06.034

广州医药 ›› 2015, Vol. 46 ›› Issue (6): 90-91.DOI: 10.3969/j.issn.1000-8535.2015.06.034

阿司匹林在房颤抗凝治疗中的弱化

从毅¹, 金洪竹², 高鸿慈³, 文齐³

1 武汉科技大学附属天佑医院急诊科(武汉 430000)
2 武汉市汉口医院泌外甲胸科(武汉 430000)
3 湖北中医药大学(武汉 430065)

收稿日期:2015-07-22 发布日期:2021-11-30
通讯作者: 从毅,E-mail:1052965723@qq.com

The limitations of aspirin for anticoagulation in atrial fibrillation

Cong yi, Jin Hongzhu, Gao Hongci, Wen Qi

Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Wuhan 430000, China;
Hankou Hospital of Wuhan,Wuhan 430000, China;
Hubei University of Traditional Chinese Medicine Wuhan,43000,China

Received:2015-07-22 Published:2021-11-30

摘要/Abstract

摘要： 目的研讨阿司匹林广泛用于高危血栓、栓塞抗凝的预防治疗应用。方法查阅参考文献,结合临床实践,新口服抗凝药疗效终点卒中和体循环栓塞方面为基准。结果界於CHADS2和CHA2DS2-VASc 评分所涵盖的风险和差异因素,后期华法林与新口服抗凝药可能取舍或并存。结论在危险分层,卒中抗拴防凝治疗中,我国房颤患者不建议继续服用阿司匹林。

关键词: 阿司匹林, 心房颤动, 抗凝治疗

Abstract: Objective To Study and discuss the applications for prevention and treatment of high risky thrombosis and embolism anticoagulation of Aspirin. Methods Combining literature consultation and clinical practice,making stroke and general circulation embolism of oral anticoagulant curative effect terminal point as the base. Results According to the risky and different factors covered by CHADS2 and CHA2DS2-VASc in the later stage, warfarin and the new oral anticoagulant can be taken together or abandon one of them. Conclusion In the risky factors classification and stroke anticoagulant therapy, we suggest that the atrial fibrillation patients should not take Aspirin.

Key words: Aspirin, Atrial fibrillation, Anticoagulant therapy

从毅, 金洪竹, 高鸿慈, 文齐. 阿司匹林在房颤抗凝治疗中的弱化[J]. 广州医药, 2015, 46(6): 90-91.

Cong yi, Jin Hongzhu, Gao Hongci, Wen Qi. The limitations of aspirin for anticoagulation in atrial fibrillation[J]. Guangzhou Medical Journal, 2015, 46(6): 90-91.

参考文献

[1] January Ct, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:areport of the American College of Cardiology/American heart Association task force on practice guidelines and the Heart Rhythm Society[J/OL],J AmCollCardiol,2014[2014-04-16].pii:S0735-1097(14)01740-9.
[2] Camm AJ, Lip Gy De, Caterina R,et al. 2012 focused update of the ESC Guidelines for the management of atrial fihrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J,2012(33):2719-2747.
[3] 相艳敏、颜红兵,朱俊,等.解读美国心脏协会/美国心脏病学学会/心律学会最新心房颤动治疗指南[J]. 中华心血管病杂志,2014,42(11):971.
[4] Tse HF, Wang YJ, Ahmed Ai-Abdullah M,et al, Stroke Prevention in atrial fibrillation-an Asian stroke perspective[J]. Heatt Rhythm, 2013(10):1082-1088.
[5] 朱俊,胡大一.关于我国非瓣膜病心房颤动血栓栓塞危险评分意见[J]. 中华心血管病杂志,2013;41(3):181-182.
[6] 中国国家处方集编委会.中国国家处方集化学药品与生物制品卷[M]. 北京:人民军医出版社,2011:195.
[7] 葛均波徐永健主编.内科学[M]. 8版.人民卫生出版社,2013:189.
[8] 国家药典委员会编.临床用药须知化学药和生物制品卷[M]. 人民卫生出版社,2005:698
[9] 国家药典委员会编.临床用药须知化学药和生物制品卷[M]. 北京:中国医药科技出版社,2011:968.
[10] 李晓红,董建增,马长生.口服抗凝药物与停药反跳[J]. 中华内科杂志,2014,53(2):147-148.
[11] Hart RG, Pearce LA, Aguilar MI. Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med,2007(146):857-867.

阿司匹林在房颤抗凝治疗中的弱化

The limitations of aspirin for anticoagulation in atrial fibrillation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	郎吉萍, 戴秋月, 吕萍, 郭志刚. 阿司匹林抗结直肠癌的作用机制的生物信息学分析[J]. 广州医药, 2021, 52(6): 23-34.
[2]	汪秀衡, 刘克皝, 刘垚, 胡恒境. I¹³¹联合TSH抑制治疗对术后中高危组甲状腺乳头状癌患者心肌纤维化及心房颤动的影响[J]. 广州医药, 2021, 52(4): 40-44.
[3]	李伟娜. 阿司匹林联合低分子肝素治疗高凝状态复发性流产的效果观察[J]. 广州医药, 2021, 52(2): 131-134.
[4]	银孟卓, 卢建文. 血浆chemerin水平与原发性高血压合并永久性心房纤颤的相关性研究[J]. 广州医药, 2018, 49(4): 13-16.
[5]	刘稳, 张伟, 李桂芹, 邱智枫, 王丽. 621例住院老老年心房颤动患者临床特点与抗凝现况分析[J]. 广州医药, 2018, 49(3): 117-119.
[6]	孔艳玲, 焦凤有, 冯硕旦, 刘晓燕, 黄巧. 长期吸烟史对高危脑卒中患者口服阿司匹林二级预防效果的影响[J]. 广州医药, 2017, 48(4): 60-63.
[7]	孙少喜, 雷晓明, 吕磊, 刘震, 彭健. 阵发性房颤环肺静脉电隔离术治疗对左心房结构和功能的影响[J]. 广州医药, 2015, 46(5): 56-57.
[8]	张勋梦, 孟庆奇, 王敏, 唐盛辉, 奉振成, 李斯明. 抗凝治疗对全膝关节表面置换术后疗效的影响[J]. 广州医药, 2015, 46(3): 19-21.